评估肌少症作为局部晚期头颈部鳞状细胞癌的预后生物标志物
Evaluation of sarcopenia as a prognostic biomarker in locally advanced head and neck squamous cell carcinoma.
作者信息
Erul Enes, Guven Deniz C, Ozbay Yakup, Altunbulak Ahmet Y, Kahvecioglu Alper, Ercan Fatih, Yesil Muhammed F, Ucdal Mete T, Cengiz Mustafa, Yazici Gozde, Kuscu Oguz, Suslu Nilda, Gullu Ibrahim, Onur Mehmet R, Aksoy Sercan
机构信息
Department of Internal Medicine, Hacettepe University, Ankara, 06230, Turkey.
Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, 06230, Turkey.
出版信息
Biomark Med. 2023 Jan;17(2):87-99. doi: 10.2217/bmm-2022-0748. Epub 2023 Apr 12.
We aimed to evaluate the effect of sarcopenia on survival in head and neck squamous cell carcinoma patients treated with chemoradiotherapy. Disease-free survival and overall survival were compared according to cervical computed tomography for radiotherapy in 123 sarcopenic and non-sarcopenic patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiotherapy with weekly cisplatin. In multivariate analyses, pretreatment sarcopenia was associated with lower disease-free survival (hazard ratio: 2.60; 95% CI: 1.38-4.87; p = 0.003) and overall survival (hazard ratio: 2.86; 95% CI: 1.40-5.85; p = 0.004). Sarcopenic patients experienced more frequent radiotherapy-related toxicities and platinum-related side effects than non-sarcopenic patients. Sarcopenia could be a potential biomarker to predict prognosis and treatment toxicity in head and neck squamous cell carcinoma.
我们旨在评估肌肉减少症对接受放化疗的头颈部鳞状细胞癌患者生存的影响。对123例接受每周顺铂同步放化疗的局部晚期头颈部鳞状细胞癌的肌肉减少症患者和非肌肉减少症患者，根据放疗用颈部计算机断层扫描比较无病生存期和总生存期。在多变量分析中，治疗前肌肉减少症与较低的无病生存期（风险比：2.60；95%置信区间：1.38 - 4.87；p = 0.003）和总生存期（风险比：2.86；95%置信区间：1.40 - 5.85；p = 0.004）相关。与非肌肉减少症患者相比，肌肉减少症患者出现放疗相关毒性和铂类相关副作用的频率更高。肌肉减少症可能是预测头颈部鳞状细胞癌预后和治疗毒性的潜在生物标志物。
Zotero 插件